This prospective observational study will evaluate the evolution of lung cancer related symptoms and their correlation with the disease control rate (complete response, partial response and stable disease) in patients with non-small cell lung cancer initiating first-line treatment with standard platinum-based chemotherapy with or without Avastin (bevacizumab). Data will be collected from each patient at baseline and after 4-6 cycles of chemotherapy.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Histologically or cytologically confirmed non-small cell lung cancer
• Initiating first-line treatment with standard platinum-based chemotherapy, with or without bevacizumab

Exclusion Criteria:

• Contraindications to the use of platinum-based chemotherapy

Non-small cell lung cancer patients initiating treatment with platinum-based chemotherapy +/- bevacizumab